- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06507787
주요 우울증 에피소드를 나타내는 환자의 건강 상태에 대한 EDIT-B® 혈액 검사의 영향 평가. 임상적 유용성과 의료경제적 측면 (SEM EDIT-B)
Depression is one of the most common mental disorders, affecting nearly 10% of men and 20% of women worldwide. It is associated with a significant increase in mortality, mainly due to suicidal behavior. The Diagnostic and Statistical Manual of Mental Disorders (DSM) defines a Major Depressive Episode (MDE) by a combination of at least five different symptoms, with at least one depressed mood or loss of interest. MDEs can occur in isolation or as part of Major Depressive Disorder (MDD) or bipolar disorder (BD). Bipolar disorders affect 2% of the world's population and are defined by episodes of mania (Type I BD) or hypomania (Type II BD) alternating with episodes of depression and periods of remission.
Depression occurring whether in the context of BD or MDD is defined with the same clinical criteria. However, the pharmacological treatments are different in the two groups. In particular, antidepressants prescribed without a thymoregulator in bipolar patients can lead to a worsening of the episode, favoring suicidal behavior or a manic turn.
The average interval between the onset of BD symptoms and appropriate diagnosis is estimated to be approximately 7 years, which delays appropriate management and treatment and increases the risk of suicide.
Biological markers able to differentiate between the different types of depression were lacking before the advent of EDIT-B®; one of the main objectives of this research is to measure the clinical impact of the use of EDIT-B® in the short and medium term on the management of patients with BD and major depression. The health economic aspect will also be considered.
In total, 450 patients in two different groups (EDIT-B® group and control group) will be recruited over a study timeline of 24 months. Study participation is over 6 months with 4 visits.
연구 개요
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: Benjamin Dubuc
- 이메일: benjamin.dubuc@alcediag-alcen.com
연구 연락처 백업
- 이름: Mary Menhem, PharmD, MSc
- 전화번호: +33788970700
- 이메일: mary.menhem@alcediag-alcen.com
연구 장소
-
-
-
Erstein, 프랑스
- 아직 모집하지 않음
- CH Erstein
-
연락하다:
- Geraldine Pfleger, Dr
- 전화번호: +33 3 90 64 21 46
- 이메일: geraldine.pfleger@ch-erstein.fr
-
수석 연구원:
- Geraldine Pfleger, Dr
-
Issy-les-Moulineaux, 프랑스
- 아직 모집하지 않음
- AP-HP Corentin Celton
-
연락하다:
- Nicolas Hoertel, Pr
- 전화번호: +33 1 58 00 44 21
- 이메일: nicolas.hoertel@aphp.fr
-
수석 연구원:
- Nicolas Hoertel, Pr
-
La Roche-sur-Foron, 프랑스
- 아직 모집하지 않음
- Etablissement Public de Santé Mentale (EPSM) 74
-
연락하다:
- Rocco De Filippis, Pr
- 전화번호: +33 749121443
- 이메일: defilippis-r@ch-epsm74.fr
-
수석 연구원:
- Rocco De Filippis, Pr
-
Lyon, 프랑스
- 모병
- Clinique Villa des Roses
-
연락하다:
- Pascal Frilloux, Dr
- 전화번호: +33 4 78 15 00 00
- 이메일: pascal.frilloux-ext@inicea.fr
-
수석 연구원:
- Pascal Frilloux, Dr
-
Montrond-les-Bains, 프랑스
- 모병
- Clinique Le Clos Montaigne
-
연락하다:
- Christophe Aimo, Dr
- 전화번호: +33 4 77 36 01 00
- 이메일: christophe.aimo@inicea.fr
-
수석 연구원:
- Christophe Aimo, Dr
-
Paris, 프랑스
- 모병
- GHU Paris Psychiatrie et Neurosciences
-
연락하다:
- Juan Zambrano
- 전화번호: +33145658153
- 이메일: juan.zambrano@ghu-paris.fr
-
수석 연구원:
- Chantal Henry, Pr
-
Ville-d'Avray, 프랑스
- 아직 모집하지 않음
- Clinique Médicale de Ville d'Avray
-
연락하다:
- Jérôme Dischamps
- 전화번호: +33147094314
- 이메일: jdischamps@wanadoo.fr
-
수석 연구원:
- Jérôme Dischamps
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Patients with a MDE, moderate to severe (DSM V criteria and MADRS score ≥19)
-
Age between 18 and 65 years, gender indifferent
-
Benefitting from health insurance coverage
-
Having signed an informed consent and agreed to follow the study protocol to completion
-
Patients for whom there is doubt regarding a bipolar disorder diagnosis, and/or presenting one or more of the following criteria:
- More than 3 episodes of MDE in personal medical history
- Psychotic symptoms
- Family history of bipolar disorder
- Onset of the first MDE before the age of 25
- Atypical symptoms or mixed features during depressive episodes
- Addiction
- Personal history of suicide attempts
- Resistance to antidepressants
- Postpartum depression within 6 months of birth
Exclusion Criteria:
- Depression in the context of schizophrenia or autism spectrum disorder
- Patient with a well-established diagnosis of bipolar disorder
- Patients who is already receiving a mood stabilizer
- Severe somatic diseases that may interfere with the follow-up or associated with treatments at risk of secondary manic decompensation
- Neurodegenerative diseases
- Pregnant women
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 특수 증상
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: With EDIT-B test result
The investigator will have the EDIT-B® test result to guide the treatment strategy. |
EDIT-B® is the first blood test for the differential diagnosis of bipolar disorder (BD) and major depression. It consists of a biological analysis (including targeted RNA sequencing) followed by a software interpretation thanks to an algorithm developed with AI. The test is CE marked, clinically validated on two independent cohorts and shows an excellent performance with a sensitivity and specificity of more than 80%. For performing the test, a blood sample of 2.5 ml will be drawn using PAXgene™ Blood RNA tubes (Becton Dickinson, UK) according to the manufacturer's instructions. The objective of EDIT-B® is to reduce the time to diagnosis of BD, which is currently 7 years on average. This will improve the patient pathway, thanks to faster access to appropriate care - whether for unipolar or bipolar patients - with a major medical, social and financial impact. |
|
위약 비교기: Without EDIT-B test result
The investigator will not have the EDIT-B® test result, but EDIT-B® is still performed on participants in the beginning of the study. |
EDIT-B® is the first blood test for the differential diagnosis of bipolar disorder (BD) and major depression. It consists of a biological analysis (including targeted RNA sequencing) followed by a software interpretation thanks to an algorithm developed with AI. The test is CE marked, clinically validated on two independent cohorts and shows an excellent performance with a sensitivity and specificity of more than 80%. For performing the test, a blood sample of 2.5 ml will be drawn using PAXgene™ Blood RNA tubes (Becton Dickinson, UK) according to the manufacturer's instructions. THE RESULT OF THE TEST WILL NOT BE GIVEN TO THE PARTICIPANT BEFORE THE END OF THE STUDY. The objective of EDIT-B® is to reduce the time to diagnosis of BD, which is currently 7 years on average. This will improve the patient pathway, thanks to faster access to appropriate care - whether for unipolar or bipolar patients - with a major medical, social and financial impact. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Improvement in depressive symptoms between inclusion and 15-16 weeks visit.
기간: 4 months (from inclusion visit to 15-16 weeks visit)
|
Clinically meaningful improvement at week 15-16 in depressive symptoms, defined as a 6-point or greater reduction in MADRS total score from baseline, without a manic switch, defined as an increase in the YMRS total score above 11 from baseline, measured using a composite endpoint. |
4 months (from inclusion visit to 15-16 weeks visit)
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .